Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Roivant Sciences Ltd. (ROIV) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
ROIV - Roivant Sciences Ltd.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$46.14
DETAILS
HIGH:
$55.00
LOW:
$40.00
MEDIAN:
$46.00
CONSENSUS:
$46.14
UPSIDE:
13.03%
Stock News
Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Roivant Sciences Ltd. (ROIV) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Roivant Sciences Ltd. (ROIV) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript
Roivant Sciences Ltd. (ROIV) Discusses Top Line Results from PHocus Study of Mosliciguat in PH-ILD Transcript
Stock Futures Mixed to Start Holiday-Shortened Week
Stock futures are mixed to start the shortened week as oil prices rise
Roivant Stock Surges on 'Robust' Data from Rare Lung Disease Candidate
Pulmovant, a clinical-stage biotech and Roivant (NASDAQ:ROIV) company, on Tuesday shared topline data from its Phase 2 PHocus clinical trial evaluating mosliciguat for pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Roivant's experimental lung disease drug meets goals in mid-stage study
Roivant said on Tuesday its experimental drug met the main goals of a mid-stage study in patients with high blood pressure associated with a type of lung disease, sending shares up about 20% in premarket trading.
Roivant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
BASEL, Switzerland and LONDON and NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. The results will be presented today at the European Respiratory Society (ERS) International Congress 2026.
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
WALTHAM, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced positive results from its Phase 2 PHocus clinical trial evaluating mosliciguat for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), a progressive and life-threatening condition with significant unmet medical needs for patients. The results will be presented today at the European Respiratory Society (ERS) International Congress 2026.
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension.
Roivant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026, and Host Investor Call
BASEL, Switzerland and LONDON and NEW YORK, Sept. 06, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) and Pulmovant today announced that results from the Phase 2 PHocus study of mosliciguat in patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) will be presented at the European Respiratory Society (ERS) International Congress 2026 at 12:15 CEST (6:15 a.m. ET) on Tuesday, September 8, 2026, by Marc Humbert, MD, PhD, Professor of Respiratory Medicine at Université Paris-Saclay and Director of the French National Reference Center for Pulmonary Hypertension. Roivant will also host an investor call and webcast at 8:00 a.m. ET on Tuesday, September 8, 2026.
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences Ltd. (ROIV) Discusses FDA Approval of LISRAYA as First Oral Targeted Therapy for Dermatomyositis Transcript
Roivant Sciences Wins FDA Approval for LISRAYA in Dermatomyositis, Launches Immediately
Roivant Sciences NASDAQ: ROIV said the U.S. Food and Drug Administration has approved LISRAYA, its once-daily oral therapy for adults with dermatomyositis, and that the drug has already entered commercial launch.
Roivant, Priovant launch newly approved rare disease drug Lisraya at $35,000 a month
Roivant and partner Priovant Therapeutics on Friday set a list price of $35,000 for a 30-day supply of their newly approved rare disease drug, Lisraya.
US FDA approves Roivant-Priovant's skin and muscle disease drug
The U.S. Food and Drug Administration said on Thursday it approved a treatment from Roivant and partner Priovant Therapeutics for a rare disease, making it the first oral drug for the condition affecting skin and muscles.
Roivant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
BASEL, Switzerland and LONDON and NEW YORK, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily.
Priovant Announces FDA Approval of LISRAYA™ (brepocitinib) for Adults with Dermatomyositis; Now Available in the U.S.
DURHAM, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has approved LISRAYA™ (brepocitinib) 30 mg for the treatment of adults with dermatomyositis (DM). LISRAYA is a pill taken once daily.
JAMA Dermatology Publishes Skin-Specific Outcomes from Phase 3 VALOR Trial Of Brepocitinib in Dermatomyositis
DURHAM, N.C., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Priovant Therapeutics announced today the publication in JAMA Dermatology of skin-specific outcomes from the Phase 3 VALOR trial evaluating brepocitinib, a first-in-class oral TYK2 and JAK1 inhibitor, in adults with dermatomyositis (DM). Primary efficacy and safety results from the trial were previously published in the New England Journal of Medicine, including benefit on measures of skin disease, muscle strength, physical function, and steroid-sparing.
Roivant Sciences: The Balance Sheet Has Become A Strategic Weapon
Roivant Sciences is transitioning from an asset-monetization platform to a commercial-stage biopharma, supported by a strong cash position and imminent product launches. ROIV's $4.7 billion pro forma liquidity eliminates near-term dilution risk, enabling commercialization of brepocitinib and continued pipeline investment without adverse equity market reliance. Brepocitinib's FDA Priority Review for dermatomyositis, with potential approval by September 2026, anchors near-term upside, while label expansions target a >280,000 patient opportunity.
Roivant Sciences Q1 Earnings Call Highlights
Roivant Sciences NASDAQ: ROIV said it expects a busy second half of 2026, with a potential launch of brepocitinib in dermatomyositis, several clinical readouts and additional regulatory discussions across its pipeline.
Price Targets
Roivant Sciences (ROIV) PT Raised to $46 at Guggenheim
$46.00
(was $41.48)
Yastin Suneja
·
Guggenheim
Roivant Sciences (ROIV) PT Raised to $55 at TD Cowen
$55.00
(was $41.48)
UBS
Roivant Sciences price target raised to $47 from $41 at H.C. Wainwright
$47.00
(was $42.03)
H.C. Wainwright
Roivant Sciences price target raised to $52 from $42 at Jefferies
$52.00
(was $41.70)
Jefferies
Roivant Sciences price target raised to $41 from $34 at H.C. Wainwright
$41.00
(was $35.12)
Douglas Tsao
·
H.C. Wainwright
Roivant Sciences price target raised to $36 from $30 at Guggenheim
$36.00
(was $29.96)
Yastin Suneja
·
Guggenheim
Roivant Sciences price target raised to $41 from $38 at TD Cowen
$41.00
(was $32.18)
Cowen & Co.
Roivant Sciences (ROIV) PT Raised to $42 at Leerink
$42.00
(was $32.41)
David Risinger
·
Leerink Partners
Roivant Sciences assumed with an Overweight at Piper Sandler
$40.00
(was $29.26)
Piper Sandler
Roivant Sciences (ROIV) PT Raised to $34 at H.C. Wainwright
$34.00
(was $28.81)
Douglas Tsao
·
H.C. Wainwright
Roivant Sciences price target raised to $33 from $26 at H.C. Wainwright
$33.00
(was $27.67)
H.C. Wainwright
Roivant Sciences price target raised to $30 from $24 at Jefferies
$30.00
(was $26.45)
Jefferies
Roivant Sciences price target raised to $30 from $28 at Guggenheim
$30.00
(was $25.82)
Guggenheim
Roivant Sciences price target raised to $28 from $25 at Guggenheim
$28.00
(was $22.30)
Guggenheim
Roivant Sciences (ROIV) PT Raised to $32 at Leerink Partners
$32.00
(was $22.09)
David Risinger
·
Leerink Partners
Roivant Sciences price target raised to $26 from $23 at H.C. Wainwright
$26.00
(was $21.46)
H.C. Wainwright
Roivant Sciences (ROIV) PT Raised to $25 at Guggenheim
$25.00
(was $20.56)
Yastin Suneja
·
Guggenheim
Roivant Sciences (ROIV) PT Raised to $29 at Leerink Partners
$29.00
(was $21.17)
David Risinger
·
Leerink Partners
Roivant Sciences price target raised to $20 from $18 at Jefferies
$20.00
(was $15.47)
Jefferies
Roivant Sciences price target raised to $21 from $15 at Guggenheim
$21.00
(was $15.24)
Guggenheim